2010-2020: Evolution of the
Longevity Industry
from Zero to 1.0
-
The Industrialization of Longevity
-
The Current State of Longevity Science, Business, Finance, and Practical Applications
-
Longevity Becomes National Priority Item for the Strategic Agenda of Progressive Governments
-
Transforming the Challenge and Deficit of Aging into the Opportunity and Asset of Longevity
-
Defining and De-Risking: Hype vs. Reality
Health as New Wealth. Longevity FinTech, WealthTech and the Coming Rise of Longevity Banks, Investment Banks, Stock Exchanges, ETFs, Indices and Novel Financial Instruments and Derivatives
-
Engineered InvestTech and FinTech Solutions to Bridge the Big Liquidity Gap
-
Longevity Futures, Shorting, Exchange Traded Funds and Technology Marketplaces
-
Longevity Stock Exchange, Investment Bank, Index Fund and Financial Derivatives
-
Financial Futurism: Derivatives Tied to National Healthcare Systems, Pension Systems, National Healthy Longevity & Longevity Economies
About the Book:
Introducing Longevity Financial Industry
PART I.
Defining the Longevity Financial Industry
-
Introduction
-
What is Longevity Finance?
-
Major Financial Corporations Re-Tuning their Business Models to Neutralize the Risk of Ageing Population and Capture the Opportunity of Healthy Longevity
-
The Need for Longevity Finance: Health as the New Wealth (Where Healthspan Meets Weathspan)
-
Longevity Finance Big Data Analytical Dashboard
-
Top Longevity Challenges and Opportunities for Financial Corporations
PART II.
The Present State of the Longevity Financial Industry (2023)
-
The Rise of Longevity Finance at the Intersection of Population Ageing vs. Longevity
-
The State of Global Longevity Finance in 2023
-
Longevity Finance Benchmarking: Top Longevity Financial Corporations in 2023
-
Longevity FinTech Benchmarking: Top Longevity FinTech Companies in 2023
-
Longevity Banking Card (Integrated AgeTech/HealthTech/WealthTech Solution)
-
Biomarkers of Human Longevity as Catalyst for Investment De-Risking, Reliable Clinical Forecasting, and Tangible Metrics for Company Valuation and Due Diligence
-
The Big Longevity Liquidity Gap
-
Longevity Investment Digest
PART III.
The Near Future of Longevity Finance (2024-2030)
-
Forecast on the Near Future of Longevity Finance: 2024-2025
-
Longevity Investment Bank
-
The Next 5 Years Will Determine the Fate of Financial Corporations at the Intersection of Ageing Population vs. Health Human Longevity
-
Longevity Banking: the 1+ Trillion Opportunity of 1 Billion People in Retirement
-
Longevity Innovation Marketplace
-
Longevity Stock Exchange
-
Longevity Exchange Traded Funds
-
Longevity Financial Instruments and Derivatives 1.0 (2024-2025)
PART IV.
The Future of Longevity Finance (2025 - 2030)
-
Longevity Financial Instruments and Derivatives 2.0 (2025-2030)
-
The Paradigm Shift From National Economies to National Longevity Economies
-
Longevity Financial Industry as the Key Mechanism for Securing the Future of Longevity Industrialization (and the Stability of National Economies)
-
The Concept of the Longevity Finance Valley: Global Benchmarking of Top Contenders to Create the First Municipal Longevity Finance Hub by 2025
-
The Evolution of the Longevity Finance State: Global Benchmarking of Top Contenders to Create the First National Longevity Finance Hub by 2030
-
Forecast on the Deep Future of Longevity Finance: 2025-2030
-
Only Longevity Finance Can Secure the Health & Wealth
About the Book: Longevity Financial Industry
In “Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History”, we distilled the complex assembly of deep market intelligence and industry knowledge that Deep Knowledge Group has developed over the past 8 years into a full-scope understanding of the global Longevity Industry, showing the public exactly how the international consortium of commercial and non-profit entities managed to define the overwhelmingly complex and multidimensional Longevity Industry for the first time, and how they created tangible framework for its systematization and forecasting. One of that book’s four major parts was devoted to the recent rise, present state and near future of the Longevity Financial Industry.
Now, as the pace of innovation and diversification in Longevity Finance continues to grow, with increasing numbers of Financial Corporations on-boarding the topic of Longevity, the time has come for a full book dedicated to this topic. In “Longevity Financial Industry: Health as New Wealth, Engineered Solutions to Bridge the Longevity Liquidity Gap, and the Rise of Longevity Investment Banks, Stock Exchanges and Financial Instruments”, Deep Knowledge Group General Partner Dmitry Kaminskiy charts the near and far future of Longevity Finance, charting the emerging paradigm of Health as New Wealth and the increasing need for weathspan extension to match the pace of increasing healthspans, forecasting the rise of Longevity-focused Retail Banks, Investment Banks, Stock Exchanges, ETFs, Technology Marketplaces and Modern Financial Instruments and Derivatives, and offering a glimpse at Deep Knowledge Group’s blueprint for modern, engineered InvestTech solutions to bridge the Big Longevity Liquidity Gap.
Longevity Financial Industry -
Foreword by Dmitry Kaminskiy
In our 2020 book, ‘Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History’, we distilled the complex assembly of deep market intelligence and industry knowledge that Deep Knowledge Group and its Longevity-focused subsidiaries (including Longevity.Capital and Aging Analytics Agency) have developed over the past 7 years into a full-scope understanding of the global Longevity Industry.
One of the four sections of that book was dedicated to the topic of Longevity Finance, charting the ways in which increasing numbers of Financial Corporations are re-tuning their business models to neutralize the challenge of ageing population and leverage the growth potential and opportunity of Longevity. Now, in 2023, given the unrecognized importance of this sector to the health and stability of the Global Longevity Industry as a whole, the time has come to devote an entire topic of the present state and near-future of this rapidly evolving sector.
While the majority of practical outcomes in healthy human longevity will be driven by precision health technologies, they will also require an assembly of other, non-biomedical components, including financial products and services such as InsurTech, AgeTech, HealthTech, and WealthTech. Progressive financial corporations are already onboarding the topic of longevity in significant ways. Meanwhile, increasing numbers of HWNIs and members of the global investment community are embracing the emerging paradigm of Health as New Wealth, and recognizing Health as the Most Precious Asset; in 2018 UBS bank conducted a survey among its HNW clients and found that 50% planned to live past the age of 100 years. It stands to reason that such clients will require a far longer horizon of financial planning and specifically designed financial products.
Against this backdrop of activities, the continued positive trajectory of growth and stability of Global Longevity Industrialization faces a major bottleneck and risk factor: Longevity start-ups require increasingly large levels of funding to move forward, and appetite for exposure to Longevity among both individual and institutional members of the convervative investment community continues to mount, but an extreme lack of innovation in the technologies, institutions, and instruments used to direct and manage Longevity investment and financial activities has created a critical Big Gap preventing the two sides of the Longevity Liquidity equation from being bridged.
Having been actively conducting market intelligence in this space for several years, and having originally coined the term Longevity Financial Industry in 2017, Deep Knowledge Group has been systematically applying its DeepTech Engineering mindset to this issue, developing and designing the blueprint of frameworks, institutional structures, technologies and financial innovations required to bridge this big gap and achieve a massive acceleration in the rate of Longevity Industrialization. Now, for the first time, we are unveiling parts of this blueprint to the larger investment and finance communities, outlining the major challenges and opportunities in this space for Investment Banks, Insurance Companies, Pension Funds, Asset Management Firms and Retail Banks, and forecasting the rise of Longevity-focused Investment Banks, Stock Exchanges, ETFs, Technology Marketplaces and Modern Financial Instruments and Derivatives, and offering a glimpse at Deep Knowledge Group’s ongoing work to create, validate and deploy the exact modern DeepTech tools and engineered solutions needed to unleash the Future of Longevity Finance years ahead of schedule.
PART I: Defining the Longevity Financial Industry
-
Introduction
-
What is Longevity Finance?
-
Major Financial Corporations (Insurance Companies, Pension Funds, Asset Management Firms, etc) Beginning to On-Board Topic of Longevity
-
The Need for Longevity Finance: Health as the New Wealth (Where Healthspan Meets Weathspan)
-
Longevity Finance Big Data Analytical Dashboard
Longevity Industry: Multi-trillion Dollar Opportunity
Longevity Financial Industry Framework
Longevity Finance: Defining the Sector
Global Financial Services Market Volume
(Forecast, $ Billions)
-
Longevity has become a major focus of some of the largest financial institutions in the world, with many major institutional investors seeking opportunities to contribute to the development of the Longevity industry by investing in AgeTech, Longevity Fintech, Longevity Biomedical companies, and startups.
-
Aging has become more than a challenge at the intersection of many of the most acute problems of our time - it also presents one of the most promising opportunities.
-
Financial institutions that will be able to adapt their business models to the new industries of AgeTech, WealthTech, and Longevity Finance will have a chance to outperform their competitors and grow rapidly. High-quality analytics on how Longevity can be on-boarded into financial institutions’ business models will help make this opportunity a reality.
-
We define 5 categories of companies that contribute to the development of the Longevity Financial Institutions industry: Asset Management Firms, Banks, Insurance, Reinsurance Companies, and Pension Funds. We expect the Longevity Finance market to grow at an average rate of 6% CAGR, reaching $28,532 billion by 2025.
Longevity Finance: Defining the Sector
-
Deep Knowledge Group’s Longevity focused analytical subsidiary Aging Analytics Agency was the first to coin the term “Longevity Financial Industry” in their May 2018 analytical report “Longevity Industry Landscape Overview Volume II: The Business of Longevity”, forecasting the rise of Longevity Finance institutions (such as Longevity Stock Exchanged, Index Funds and AgeTech Banks) and instruments (specialized financial derivatives tied to the Longevity Industry) as far back as Q2 2018, and was the first to produce a dedicated analysis of the sector, and a specific analytical framework capable of defining the sector and forecasting developments within it, through their July 2019 special analytical case study “Advancing Financial Industry: Longevity / AgeTech / WealthTech”.
Top-20 Financial Institutions Advancing the Longevity Industry
300 Longevity Finance Institutions: Regional Proportion
-
The above chart represents the distribution of Longevity-focused financial institutions by country. On the one hand, the largest number of the selected companies have their headquarters in the US because of the high availability of developed financial markets there. On the other hand, quite a few companies are headquartered in the UK and in the EU for similar reasons.
Financial Institutions Advancing the Longevity Industry
-
Since the Q1 2020 global financial market downturn, 194 financial institutions have fully recovered by year-end and continued to grow in 2021.
-
The largest institutions involved in the Longevity Finance sector by market capitalization include Berkshire Hathaway, JPMorgan Chase & Co., Industrial and Commercial Bank of China, and Shell Contributory Pension Fund.
-
Given that many Longevity-advancing financial institutions are included in the S&P 500, this chart represents the approximate dynamics of the entire stock market.
PART II: The Present State of the Longevity
Financial Industry (2023)
-
The Rise of Longevity Finance at the Intersection the Opposed MegaTrends of Population Ageing vs. Healthy Human Longevity
-
The Rise of the Silver Dollar: The Multi-Trillion Opportunity of 1 Billion People in Retirement
-
The State of Global Longevity Finance in 2023
-
Global Longevity Finance Benchmarking: Top Longevity Financial Corporations in 2023
-
Global Longevity FinTech Benchmarking: Top Longevity FinTech Companies and Startups in 2023
-
Longevity Banking Card
(Integrated AgeTech/HealthTech/WealthTech Solution) -
Biomarkers of Human Longevity as Major Catalyst for Investment, InsurTech, Longevity Stock Exchange and Financial Instruments
-
Biomarkers of Human Longevity for InsurTech: Spotlight / Case Study
-
The Big Longevity Liquidity Gap
-
Longevity Investment Bank
Top-300 Financial Institutions Advancing Financial Industry Longevity/AgeTech/WealthTech
Number of Financial Institutions Engaged
in the Longevity Sector by Region
Total Market Capitalization of Financial Institutions Engaged in the Longevity Sector in 2023: Regional Distribution
Top 10 Financial Institutions Advancing the Longevity Industry
in 2023 (by Market Capitalization)
The Biggest Financial Institutions Advancing
the Longevity Industry
-
4 of the 5 biggest financial institutions (by market capitalization) advancing the Longevity Industry are represented by banks. Nevertheless, the first place is taken by Berkshire Hathaway asset management firm.
Despite the Covid-19 financial crisis that occurred in the beginning of 2020, nearly all financial institutions have recovered their market capitalization to pre-pandemic figures and some of them such as Berkshire Hathaway and JPMorgan Chase & Co. have reached even higher positions by the beginning of 2021.
Biomarkers of Human Longevity for Investment De-Risking, Reliable Clinical Forecasting, and Tangible Metrics for Company Valuation and Due Diligence
-
The Longevity Industry’s Systemic and Most Fundamental Risk: Reliance on Animal Model (Mice) Data for Company Valuation
-
Lack of tangible frameworks for human validation is leading to unstable market capitalization dynamics for public Longevity companies, and risks de-stabilizing long-term investor confidence Biomarkers of Human Longevity as the only market-ready tool to de-risk Longevity investing
-
Consensus frameworks of Biomarkers of Human Longevity to bridge the translational gap of successful results in model organisms (mice) vs. replication of results in humans (clinical trials)
-
Tangible biomarker-based frameworks for company valuation and due diligence, as the tool for reliable investor expectations and forecasts
-
Digital Human Avatars as the platform for safe self-experimentation and real-time therapeutic validation, personalization and fine-tuning
-
Longevity Economy 2.0 — Biomarkers of Human Longevity as Major Catalyst for Longevity Investment Bank, InsurTech, Longevity Stock Exchange and Financial Instruments and Derivatives
Digital Human Avatar Framework: 1.0, 2.0, 3.0 and 4.0
PART III: The Near Future of Longevity Finance (2023-2025)
-
Forecast on the Near Future of Longevity Finance: 2023-2025
-
What the Opposed MegaTrends of Aging Population and Advancing Biomedicine MEans for the Finance Sector
-
The Rise of the Silver Dollar: 1+ Billion Global Retired Hold the Majority of Global Purchasing Power, and Recognize Health as the New Wealth, and Longevity as Most Precious Asset Class
-
Forecasting Major Challenges and Opportunities for Pension Funds, Insurance Companies, Retail Banks, Investment Banks, Asset Management Firms, and Financial Advisory Services
-
Longevity Financial Corporations vs. Longevity FinTech Companies: Competitive Landscape Analysis
-
Longevity Innovation Marketplace
-
Longevity Stock Exchange
-
Longevity Exchange Traded Funds
-
Longevity Financial Instruments and
Derivatives 1.0 (2023-2025)
Longevity Finance Big Data Analytical Dashboard:
Data Analysis Pipeline
Longevity Banking Card: Overview of Feature
Longevity Banking Card: Marketplace Components
HealthTech Integration and Healthspan Gamification
PART IV: The Future of Longevity Finance (2025-2030)
-
Longevity Financial Instruments and Derivatives 2.0 (2025-2030)
-
The Paradigm Shift From National Economies to National Longevity Economies
-
Longevity Financial Industry as the Key Mechanism for Securing the Future of Longevity Industrialization (and the Stability of National Economies)
-
The Concept of the Longevity Finance Valley: Global Benchmarking of Top Contenders to Create the First Municipal Longevity Finance Hub by 2025
-
The Evolution of the Longevity Finance State: Global Benchmarking of Top Contenders to Create the First National Longevity Finance Hub by 2030
-
Forecast on the Deep Future of Longevity Finance: 2025-2030
Deep Knowledge Group Longevity Finance Roadmap
About the Author
Dmitry Kaminskiy is an innovative entrepreneur, investor, author and philanthropist dedicated to impact investment and ethical business, with a focus on engineering the accelerated trajectory of progressive technological development for the benefit of humanity.
Mr. Kaminskiy is a co-founder and managing partner of Deep Knowledge Group - a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, Precision Medicine, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, policy and philanthropy.
-
He leads the activities of the consortium’s venture arms - Deep Knowledge Ventures, an investment fund focused on DeepTech and advanced science projects, and Longevity.Capital, which prioritizes the convergence of Longevity and Artificial Intelligence, areas in which it has unparalleled investment and exit strategies.
-
He is a frequent speaker on the topics of AI and Longevity, including conferences organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Smart Machines vs Smart People”, at the Future Finance Forum in Seoul “AI in Finance”, “Precision Medicine World Conference" in Silicon Valley, as well as several others at Oxford and Cambridge Universities.
Mr. Kaminskiy serves as managing trustee of Biogerontology Research Foundation, the UK’s oldest Longevity focused charity.